What’s Hot and What’s Not in IO 2021?
Expert biotech and pharma stakeholders discuss the opportunities and challenges in immuno-oncology:
- Funding
- Deals
- Clinical Development
- Commercialization
SPEAKERS:

Linda Pullan, PhD - Moderator
Pullan Consulting
Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals. Learn more...

Jeffrey M. Bockman, PhD
EVP, Oncology Practice Head, Cello Health BioConsulting
Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting (Previously Defined Health). He received a BA from the University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn more...

Paul Frohna, MD, PhD
Chief Medical Officer, ImCheck
Dr. Paul Frohna is a physician-scientist with over 20 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy. Learn more...

Jacob Becraft, PhD
CEO, Co-founder, Strand Therapeutics Inc
Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Learn more...

Asthika Goonewardenes
Managing Director, Equity Research — BiotechTruist Securities
Asthika Goonewardene is a Managing Director at Truist Securities covering biotechnology companies with a focus on cell therapy, immuno-oncology, and antibody technology. Prior to joining the STRH Biotech team in 2019, Mr Goonewardene was a senior analyst with Bloomberg Intelligence, leading coverage of the global biotech sector. Learn more...
